Embecta
Sells pen needles, syringes, and newer drug-delivery devices for diabetes and chronic care.
Something off on this page? Send us feedback.
Profile
Sells pen needles, insulin syringes, safety injection products, and a small digital diabetes app business through wholesalers, distributors, and some direct channels. Most revenue still comes from pen needles, while the Owen Mumford deal broadens the portfolio into auto-injectors and other chronic-care delivery devices.
Built around diabetes injection supplies, the portfolio centers on pen needles, insulin syringes, safety pen needles, and safety syringes, plus a small digital diabetes-management offering and contract manufacturing.
Sales run primarily through wholesalers and distributors serving retail and institutional channels, with some direct or hybrid commercial arrangements by market. Revenue is split between the US and international markets, but pen needles remain the core earnings engine inside a single reported segment.
Current expansion comes from the Owen Mumford acquisition, which adds auto-injector and broader drug-delivery platforms for chronic-care settings. The business still depends on a few key product lines, outside components and raw materials, and continuing supply links that date back to the BD separation.
Company facts
Categories
Key statistics
Year to date −56.7% · Average volume (30d) 1.5M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| May 6, 2026 | Mizuho Securities | Target | $12 | $5 | ||
| May 6, 2026 | BTIG | Downgrade | Buy | Neutral | ||
| Apr 13, 2026 | Mizuho Securities | Target | $12 | |||
| Nov 27, 2024 | BTIG | Upgrade | Neutral | Buy | $26 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 7, 2026Q3 FY26 | $0.27 | $0.56 | +110.7% | $254.5M | $271.7M | +6.7% | +26.29% |
| May 5, 2026Q2 FY26 | $0.42 | $0.27 | −35.7% | $235.7M | $221.8M | −5.9% | −8.72% |
| Feb 5, 2026Q1 FY26 | $0.67 | $0.71 | +6.0% | $258.1M | $261.2M | +1.2% | +3.82% |
| Nov 25, 2025Q4 FY25 | $0.70 | $0.50 | −28.6% | $258.2M | $264.0M | +2.2% | −7.44% |
Financial highlights
| 12 quarters | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $259.0M | $295.5M | $264.0M | $261.2M | $221.8M | $271.7M | |
| Gross profit | $161.5M | $195.0M | $156.0M | $175.6M | $125.2M | $153.3M | |
| Operating income | $78.5M | $106.1M | $64.4M | $97.1M | $42.9M | $48.7M | |
| Net income | $23.5M | $45.5M | $26.4M | $44.1M | −$4.1M | $21.1M | |
| Diluted EPS | $0.40 | $0.78 | $0.45 | $0.74 | −$0.07 | $0.36 | |
| Gross margin | 62.4% | 66.0% | 59.1% | 67.2% | 56.4% | 56.4% | |
| Operating margin | 30.3% | 35.9% | 24.4% | 37.2% | 19.3% | 17.9% |
Fiscal years (4-quarter sums)FY21 $1.17B · FY22 $1.13B · FY23 $1.12B · FY24 $1.12B · FY25 $1.08B
Revenue by product · Q3 FY26
Revenue by geography · Q3 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $214.7M · Total debt $1.50B · Total assets $1.27B · Shareholders' equity −$612.7M
Dividends
Raised for 2 straight years. To collect a payout, hold shares through the close before the ex-date.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Aug 27, 2026 | Aug 27 | Sep 15 | $0.01 | |
| May 28, 2026 | May 28 | Jun 15 | $0.01 | cut from $0.15 |
| Feb 27, 2026 | Feb 27 | Mar 17 | $0.15 | |
| Dec 5, 2025 | Dec 5 | Dec 18 | $0.15 | |
| Aug 29, 2025 | Aug 29 | Sep 15 | $0.15 | |
| May 28, 2025 | May 28 | Jun 13 | $0.15 | |
| Feb 28, 2025 | Feb 28 | Mar 14 | $0.15 | |
| Dec 6, 2024 | Dec 6 | Dec 18 | $0.15 |
Ownership
Shares outstanding 59.33M · Float 58.33M · 98.3% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 4.60M | 7.75% | 13F | Aug 7, 2026 |
| Yacktman Asset Management LP | 4.32M | 7.27% | 13F | Aug 11, 2026 |
| Stowers Institute for Medical Research | 3.44M | 5.80% | 13G | May 1, 2026 |
| Vanguard Capital Management LLC | 2.56M | 4.31% | 13F | Aug 13, 2026 |
| Deerfield Management Company, L.P. (Series C) | 2.53M | 4.27% | 13F | Aug 14, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 12, 2026 | Jacob Elguicze | officer: SVP and CFO | +20,000 | $4.67 |
| Aug 12, 2026 | Devdatt Kurdikar | director, officer: President and CEO | +30,000 | $4.70 |
| Aug 12, 2026 | Robert J. Hombach | director | +45,000 | $4.97 |
| Aug 12, 2026 | Jeffrey Z. Mann | officer: Pres, Pharm Svc&Prod Mgmt, CLO | +20,000 | $4.99 |
Peers
- Novo Nordisk (ADR)
Pen needles and injection systems across diabetes therapy
- Medtronic
Automated pump therapy as a substitute for daily injections
- Insulet
Tubeless pump therapy that replaces multiple daily injections
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Embecta | $5.01 | −0.79% | $299.6M | 3.4 | 3.1 | 0.3 | −8.1% |
| Novo Nordisk (ADR) | $45.60 | +0.00% | $202.54B | 11.2 | 18.4 | 4.0 | +0.0% |
| Medtronic | $91.58 | +0.42% | $116.78B | 24.5 | 15.3 | 3.2 | +9.9% |
| Insulet | $145.31 | +0.11% | $10.05B | 27.1 | 21.0 | 3.3 | +23.5% |
| Median | 24.5 | 18.4 | 3.3 | +9.9% |